Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Schering Pharma Remains Optimistic About Growth In Asia Pacific Region, Won’t Join Acquisition Bandwagon

This article was originally published in PharmAsia News

Executive Summary

Bayer Schering Pharma has been enjoying double-digit growth in the Asia Pacific region for the past three years, and is confident in maintaining this momentum over the next few years, said Chris Lee, the company's Asia Pacific regional head. Bayer will expand its China workforce from the current 3,000 people to more than 4,000 people in the next two years. Lee said that the acquisition planned by Merck of Schering-Plough and by Pfizer of Wyeth will not pose a substantial threat to Bayer. He stressed that Bayer will not resort to an acquisition strategy as a counter-measure, and will instead rely on its strong R&D.(Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel